These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

775 related articles for article (PubMed ID: 25600436)

  • 1. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells.
    Frigault MJ; Lee J; Basil MC; Carpenito C; Motohashi S; Scholler J; Kawalekar OU; Guedan S; McGettigan SE; Posey AD; Ang S; Cooper LJ; Platt JM; Johnson FB; Paulos CM; Zhao Y; Kalos M; Milone MC; June CH
    Cancer Immunol Res; 2015 Apr; 3(4):356-67. PubMed ID: 25600436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.
    Guedan S; Chen X; Madar A; Carpenito C; McGettigan SE; Frigault MJ; Lee J; Posey AD; Scholler J; Scholler N; Bonneau R; June CH
    Blood; 2014 Aug; 124(7):1070-80. PubMed ID: 24986688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
    Milone MC; Fish JD; Carpenito C; Carroll RG; Binder GK; Teachey D; Samanta M; Lakhal M; Gloss B; Danet-Desnoyers G; Campana D; Riley JL; Grupp SA; June CH
    Mol Ther; 2009 Aug; 17(8):1453-64. PubMed ID: 19384291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
    Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo.
    Song DG; Ye Q; Poussin M; Harms GM; Figini M; Powell DJ
    Blood; 2012 Jan; 119(3):696-706. PubMed ID: 22117050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
    Wang X; Naranjo A; Brown CE; Bautista C; Wong CW; Chang WC; Aguilar B; Ostberg JR; Riddell SR; Forman SJ; Jensen MC
    J Immunother; 2012; 35(9):689-701. PubMed ID: 23090078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
    Hudecek M; Sommermeyer D; Kosasih PL; Silva-Benedict A; Liu L; Rader C; Jensen MC; Riddell SR
    Cancer Immunol Res; 2015 Feb; 3(2):125-35. PubMed ID: 25212991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 10. Versatile strategy for controlling the specificity and activity of engineered T cells.
    Ma JS; Kim JY; Kazane SA; Choi SH; Yun HY; Kim MS; Rodgers DT; Pugh HM; Singer O; Sun SB; Fonslow BR; Kochenderfer JN; Wright TM; Schultz PG; Young TS; Kim CH; Cao Y
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E450-8. PubMed ID: 26759368
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
    Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
    Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma.
    Shen CJ; Yang YX; Han EQ; Cao N; Wang YF; Wang Y; Zhao YY; Zhao LM; Cui J; Gupta P; Wong AJ; Han SY
    J Hematol Oncol; 2013 May; 6():33. PubMed ID: 23656794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
    Hombach AA; Rappl G; Abken H
    Mol Ther; 2013 Dec; 21(12):2268-77. PubMed ID: 23985696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40.
    Foster AE; Mahendravada A; Shinners NP; Chang WC; Crisostomo J; Lu A; Khalil M; Morschl E; Shaw JL; Saha S; Duong MT; Collinson-Pautz MR; Torres DL; Rodriguez T; Pentcheva-Hoang T; Bayle JH; Slawin KM; Spencer DM
    Mol Ther; 2017 Sep; 25(9):2176-2188. PubMed ID: 28697888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
    Tasian SK; Kenderian SS; Shen F; Ruella M; Shestova O; Kozlowski M; Li Y; Schrank-Hacker A; Morrissette JJD; Carroll M; June CH; Grupp SA; Gill S
    Blood; 2017 Apr; 129(17):2395-2407. PubMed ID: 28246194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
    Lee HJ; Hwang SJ; Jeong EH; Chang MH
    J Microbiol; 2024 Jul; 62(7):555-568. PubMed ID: 38700775
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2.
    Gargett T; Brown MP
    Cytotherapy; 2015 Apr; 17(4):487-95. PubMed ID: 25573334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.